Ondansetron
If you have any questions, ask your doctor or pharmacist.
Yatrox belongs to a group of medications called antiemetics. Yatrox is used for:
If you consider this applies to you, consult your doctor before taking Yatrox
Consult your doctor or pharmacist before starting to use Yatrox.
If you are to undergo any diagnostic tests (including blood, urine, skin tests that use allergens, etc.) inform your doctor that you are taking this medication, as it may alter the results.
Inform your doctor or pharmacist if you are using or have used recently or may have to use any other medication.
Particularly, it is essential to inform the doctor if you are taking any of the following medications, as it may be necessary to interrupt treatment or adjust the dose of one of them:
Inform your doctor or pharmacistif you are taking any of these medications.
Yatrox should not be used during the first trimester of pregnancy. This is because Yatrox may slightly increase the risk of a baby being born with a cleft lip and/or palate (openings or fissures in the upper lip or palate). If you are already pregnant, think you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using Yatrox. If you are a fertile woman, it is recommended that you use an effective contraceptive method.
It is unlikely that Yatrox will affect your ability to drive and operate machinery.
This medication contains lactose. If your doctor has told you that you have a certain sugar intolerance, consult with him before taking this medication.
Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Remember to take your medication. Swallow the whole tablets with a little water. Your doctor will indicate the duration of your treatment with Yatrox. Do not discontinue treatment before.
Adults
One tablet (8 mg) orally, 1-2 hours before the potentially nausea-causing medical treatment, and then one tablet (8 mg) 12 hours later.
To prevent nausea and vomiting on subsequent days, continue taking one tablet (8 mg) every 12 hours for five days.
Children over 6 months and adolescents
Your doctor will decide the dose based on your child's weight or body surface area.
Normally, 12 hours after chemotherapy, your child will receive ondansetron orally. The usual dose is 4 mg twice a day and may continue for up to 5 days.
Adults
To prevent nausea and vomiting after surgery, two tablets (16 mg) orally, 1 hour before anesthesia.
Children
No data are available on the oral administration of ondansetron for the prevention of postoperative nausea and vomiting in children.
Patients with liver insufficiency
In patients with liver problems, the dose should be adjusted to a maximum of 8 mg of ondansetron per day.
Older patients, patients with renal insufficiency or slow metabolizers ofsparteine/debrisoquine
No dose adjustment or frequency of dose or route of administration is necessary.
Your doctor will decide the duration of your treatment with Yatrox. Do not discontinue treatment before.
If you estimate that the action of this medication is too strong or too weak, inform your doctor or pharmacist.
In case of overdose, the symptoms that may appear are: vision problems, low blood pressure (which may cause dizziness or fainting) and palpitations (irregular heartbeat).
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, Teléfono 91 562 04 20, indicating the medication and the amount ingested.
Do not take a double dose to compensate for the missed doses. Do not increase or decrease the dose without your doctor's authorization.
If you forget to take a dose and experience discomfort or vomiting, take another dose as soon as possible. Then, continue taking the medication as indicated.
If you forget to take a dose and do not experience discomfort, wait for the next dose and continue taking the medication as indicated.
If you have any other questions about the use of this product, ask your doctor or pharmacist.
Like all medicines, Yatrox can cause side effects, although not everyone will experience them.
They may affectmore than 1 in 10 patientswho take Yatrox:
They may affectup to 1 in 10 patientswho take Yatrox:
They may affectup to 1 in 100 patientswho take Yatrox:
They may affectless than 1 in 1,000 patientswho take Yatrox:
If you experience any of these symptoms,stop taking the medicine immediately and inform your doctor.
They may affectless than 1 in 10,000 patientswho take Yatrox:
Inform your doctor immediatelyif you experience any of these symptoms.
Side effects of unknown frequency: cannot be estimated
The signs include:
If you experience side effects, consult your doctor, pharmacist, or nurse, even if they are not listed in this prospectus.
Adverse event reporting
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack and on the packaging after CAD. The expiration date is the last day of the month indicated.
This medication does not require special conditions for conservation.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Yatrox
The active principle is ondansetron hydrochloride dihydrate. Each coated tablet of Yatrox contains 8 mg of ondansetron (as hydrochloride dihydrate).
The other components are: lactose monohydrate, microcrystalline cellulose (E460), pregelatinized cornstarch, magnesium stearate (E470b), hypromellose (E464), titanium dioxide (E171), and polyethylene glycol 400 (E1521).
Appearance of the product and contents of the packaging
Yatrox 8 mg are white, film-coated, oblong, and biconvex tablets with the inscription “8” on one face.
Yatrox is available in packaging of 6, 15, or 500 tablets.
Only some packaging sizes may be marketed.
Holder of the marketing authorization and manufacturer responsible
Holder
Dari Pharma, S.L.U.
Gran Via Carles III, 98, 10th floor
08028 Barcelona
Spain
Manufacturer responsible
Neuraxpharm Pharmaceuticals, S.L.
Avda.Barcelona, 69
08970 Sant Joan Despí – Barcelona
Spain
Last review date of this leaflet:February 2022
The detailed information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS):http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.